This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2008 Jun 17;148(12):932-8.

doi: 10.7326/0003-4819-148-12-200806170-00220. Epub 2008 May 5.

National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease

Otis W Brawley¹, Llewellyn J Cornelius, Linda R Edwards, Vanessa Northington Gamble, Bettye L Green, Charles Inturrisi, Andra H James, Danielle Laraque, Magda Mendez, Carolyn J Montoya, Brad H Pollock, Lawrence Robinson, Aaron P Scholnik, Melissa Schori

Affiliations

PMID: 18458271
DOI: 10.7326/0003-4819-148-12-200806170-00220

Free article

National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease

Otis W Brawley et al. Ann Intern Med. 2008.

Free article

. 2008 Jun 17;148(12):932-8.

doi: 10.7326/0003-4819-148-12-200806170-00220. Epub 2008 May 5.

Authors

Otis W Brawley¹, Llewellyn J Cornelius, Linda R Edwards, Vanessa Northington Gamble, Bettye L Green, Charles Inturrisi, Andra H James, Danielle Laraque, Magda Mendez, Carolyn J Montoya, Brad H Pollock, Lawrence Robinson, Aaron P Scholnik, Melissa Schori

Affiliation

¹ American Cancer Society, 250 Williams Street, Atlanta, GA 30303, USA.

PMID: 18458271
DOI: 10.7326/0003-4819-148-12-200806170-00220

No abstract available

PubMed Disclaimer

Similar articles

NIH consensus development statement on hydroxyurea treatment for sickle cell disease.
Brawley OW, Cornelius LJ, Edwards LR, Gamble VN, Green BL, Inturrisi CE, James AH, Laraque D, Mendez MH, Montoya CJ, Pollock BH, Robinson L, Scholnik AP, Schori M. Brawley OW, et al. NIH Consens State Sci Statements. 2008 Feb 27-29;25(1):1-30. NIH Consens State Sci Statements. 2008. PMID: 18309362
Hydroxyurea for sickle cell anemia.
Bachmeyer C, Aractingi S, Lionnet F. Bachmeyer C, et al. N Engl J Med. 2008 Jul 3;359(1):98; author reply 98-9. N Engl J Med. 2008. PMID: 18609755 No abstract available.
Hydroxyurea for sickle-cell anaemia in Africa: mind the gap.
Obaro SK. Obaro SK. Lancet Glob Health. 2015 Mar;3(3):e124-5. doi: 10.1016/S2214-109X(14)70371-7. Lancet Glob Health. 2015. PMID: 25701988 No abstract available.
Hydroxyurea for the treatment of sickle cell anemia.
Platt OS. Platt OS. N Engl J Med. 2008 Mar 27;358(13):1362-9. doi: 10.1056/NEJMct0708272. N Engl J Med. 2008. PMID: 18367739 Review. No abstract available.
Hydroxyurea in very young children with sickle cell anemia is not a cure-all.
Powars DR. Powars DR. J Pediatr. 2001 Dec;139(6):763-4. doi: 10.1067/mpd.2001.120093. J Pediatr. 2001. PMID: 11743496 No abstract available.

See all similar articles

Cited by

Barriers and Facilitators of Use of Hydroxyurea among Children with Sickle Cell Disease: Experiences of Stakeholders in Tanzania.
Kilonzi M, Mlyuka HJ, Felician FF, Mwakawanga DL, Chirande L, Myemba DT, Sambayi G, Mutagonda RF, Mikomangwa WP, Ndunguru J, Jonathan A, Ruggajo P, Minja IK, Balandya E, Makani J, Sirili N. Kilonzi M, et al. Hemato. 2021 Dec;2(4):713-726. doi: 10.3390/hemato2040048. Epub 2021 Nov 28. Hemato. 2021. PMID: 39211482 Free PMC article.
Hydroxyurea mobile directly observed therapy versus standard monitoring in patients with sickle cell anemia: a phase 2 randomized trial.
Sasi P, Makubi A, Sangeda RZ, Ngaeje MY, Mmbando BP, Soka J, Rosano C, Magesa AS, Cox SE, Makani J, Novelli EM. Sasi P, et al. Commun Med (Lond). 2024 Aug 9;4(1):160. doi: 10.1038/s43856-024-00552-5. Commun Med (Lond). 2024. PMID: 39122788 Free PMC article.
Optimizing the management of inherited blood disorders in a changing market: Findings from the AMCP Market Insights Program.
Richardson T, Rice M, Haumschild R, Hoffer D, Morana S, Watkins J. Richardson T, et al. J Manag Care Spec Pharm. 2024 Jul;30(7-a Suppl):S1-S12. doi: 10.18553/jmcp.2024.30.7-a.s1. J Manag Care Spec Pharm. 2024. PMID: 38953485 Free PMC article.
Sickle cell disease and infertility risks: implications for counseling and care of affected girls and women.
Pecker LH, Cameron K. Pecker LH, et al. Expert Rev Hematol. 2024 Aug;17(8):493-504. doi: 10.1080/17474086.2024.2372320. Epub 2024 Jun 26. Expert Rev Hematol. 2024. PMID: 38913857 Free PMC article. Review.
Breaking genetic shackles: The advance of base editing in genetic disorder treatment.
Xu F, Zheng C, Xu W, Zhang S, Liu S, Chen X, Yao K. Xu F, et al. Front Pharmacol. 2024 Mar 6;15:1364135. doi: 10.3389/fphar.2024.1364135. eCollection 2024. Front Pharmacol. 2024. PMID: 38510648 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information